These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24916029)

  • 21. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
    van Loevezijn A; Venhorst J; Iwema Bakker WI; de Korte CG; de Looff W; Verhoog S; van Wees JW; van Hoeve M; van de Woestijne RP; van der Neut MA; Borst AJ; van Dongen MJ; de Bruin NM; Keizer HG; Kruse CG
    J Med Chem; 2011 Oct; 54(20):7030-54. PubMed ID: 21866910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
    J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
    J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor.
    Guscott MR; Egan E; Cook GP; Stanton JA; Beer MS; Rosahl TW; Hartmann S; Kulagowski J; McAllister G; Fone KC; Hutson PH
    Neuropharmacology; 2003 Jun; 44(8):1031-7. PubMed ID: 12763096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor.
    Moloney GP; Martin GR; Mathews N; Milne A; Hobbs H; Dodsworth S; Sang PY; Knight C; Williams M; Maxwell M; Glen RC
    J Med Chem; 1999 Jul; 42(14):2504-26. PubMed ID: 10411472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT7, but not 5-HT2B, receptors mediate hypotension in vagosympathectomized rats.
    Centurión D; Glusa E; Sánchez-López A; Valdivia LF; Saxena PR; Villalón CM
    Eur J Pharmacol; 2004 Oct; 502(3):239-42. PubMed ID: 15476750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
    Kim Y; Yeom M; Tae J; Rhim H; Choo H
    Eur J Med Chem; 2016 Mar; 110():302-10. PubMed ID: 26852005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
    Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
    J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
    Moss N; Choi Y; Cogan D; Flegg A; Kahrs A; Loke P; Meyn O; Nagaraja R; Napier S; Parker A; Thomas Peterson J; Ramsden P; Sarko C; Skow D; Tomlinson J; Tye H; Whitaker M
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2206-10. PubMed ID: 19307114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
    Kucwaj-Brysz K; Kurczab R; Jastrzębska-Więsek M; Żesławska E; Satała G; Nitek W; Partyka A; Siwek A; Jankowska A; Wesołowska A; Kieć-Kononowicz K; Handzlik J
    Eur J Med Chem; 2018 Mar; 147():102-114. PubMed ID: 29425815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
    de la Fuente T; Martín-Fontecha M; Sallander J; Benhamú B; Campillo M; Medina RA; Pellissier LP; Claeysen S; Dumuis A; Pardo L; López-Rodríguez ML
    J Med Chem; 2010 Feb; 53(3):1357-69. PubMed ID: 20078106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-Aminoethylpiperazinyl aryl ketones with 5-HT₁A/5-HT₇ selectivity.
    Kim MK; Lee HS; Kim S; Cho SY; Roth BL; Chong Y; Choo H
    Bioorg Med Chem; 2012 Jan; 20(2):1139-48. PubMed ID: 22196512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
    Shireman BT; Dvorak CA; Rudolph DA; Bonaventure P; Nepomuceno D; Dvorak L; Miller KL; Lovenberg TW; Carruthers NI
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2103-8. PubMed ID: 18282705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
    Gaster LM; Blaney FE; Davies S; Duckworth DM; Ham P; Jenkins S; Jennings AJ; Joiner GF; King FD; Mulholland KR; Wyman PA; Hagan JJ; Hatcher J; Jones BJ; Middlemiss DN; Price GW; Riley G; Roberts C; Routledge C; Selkirk J; Slade PD
    J Med Chem; 1998 Apr; 41(8):1218-35. PubMed ID: 9548813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
    Kekewska A; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
    Pauwels PJ; Gouble A; Wurch T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel quinazolinone derivatives as 5-HT7 receptor ligands.
    Na YH; Hong SH; Lee JH; Park WK; Baek DJ; Koh HY; Cho YS; Choo H; Pae AN
    Bioorg Med Chem; 2008 Mar; 16(5):2570-8. PubMed ID: 18083580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.